Process of using a tetrazolium salt

• US 7,897,331 B2
• Filed: 06/16/2010
• Issued: 03/01/2011
• Est. Priority Date: 01/14/2005
• Status: Active Grant

• Current Assignee: Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation)
• Original Assignee: Bayer Healthcare LLC (Bayer AG)
• Inventors: Albarella, James P., Marfurt, Karen L., Landi, John J., Felman, Steven W.
• Primary Examiner(s): Anderson; Rebecca L
• Assistant Examiner(s): Shterengarts; Samantha L
• Application Number:
  US12/816,793
• Publication Number:
  US 20100255506A1
• Time in Patent Office: 258 Days
• Field of Search: 435/4, 436/95, 548/146, 548/190, 548/250
• US Class Current: 435/4
• CPC Class Codes: C07D 417/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 417/14 containing three or more hetero rings
• CPC Class Codes: Y10T 436/144444 Glucose

Abstract

Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkylammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings attached to the tetrazolium ring.

Claims

1. A method of measuring an analyte contained in a biological fluid, the analyte adapted to produce a proportional color change upon a reaction, the method comprising the acts of:

providing a tetrazolium salt as an indicator, said tetrazolium salt having the formula of

2. The method of claim 1, wherein said analyte is glucose.

3. The method of claim 2, wherein said biological fluid is whole blood.

4. The method of claim 2, wherein said tetrazolium salt has the formula

5. The method of claim 4, wherein

X is propyl

b is zero

R_l is methyl

R₂ and R₃ form a methylene dioxy group

R₄ is CHF₂

R_s is Cl.

6. The method of claim 4, wherein

X is propyl

b is 1

R_l is methyl

R₂ and R₃ form a methylene dioxy group

R₄ is CHF₂

R₅ is Cl.

7. The method of claim 4, wherein

X is propyl

b is zero

R_l is methyl

R₂ is trimethylammonium propyl

R₃ is methyl

R₄ is CHF₂

R₅ is Cl.

8. The method of claim 1, wherein said tetrazolium salt has the formula

9. The method of claim 8, wherein

X is propyl

b is zero

R_l is methyl

R₂ is trimethylammonium propyl

R₃ is methyl

R₇, R₈ and R₉ are hydrogen.

10. The method of claim 8, wherein

X is propyl

R_l is methyl

b is zero

R₂ is trimethylammonium propyl

R₃ is methyl

R₇ and R₈ form an aromatic ring

R₉ is methoxy.

11. The method of claim 8, wherein

X is propyl

b is zero

R_l is methyl

R₂ is trimethylammonium propyl

R₃ is methyl

R₇ and R₈ are hydrogen

R₉ is ethoxy.

12. The method of claim 8, wherein

X is propyl

b is zero

R₁ is methyl

R₂ is trimethylammonium propyl

R₃ is methyl

R₇ and R₈ are hydrogen

R₉ is bromine.

13. The method of claim 1, wherein said counter-ion is selected from the group consisting of nitrite, phosphate, hydrogen phosphate, dihydrogen phosphate, hydrogen sulfate, sulfate, hydrogen carbonate, carbonate, methane sulfonate, fluoroborate, bromide, chloride, iodide, or combinations thereof.

14. The method of claim 1, wherein one of R₄ and R₅ is halogen and the other is a halogen substituted 1-6C alkyl.

15. The method of claim 1, wherein R₄ and R₅ are joined to form an aromatic ring.

16. The method of claim 15, wherein R₄ and R₅ are joined to form a 6-membered aromatic ring.

17. The method of claim 1, wherein one of R₄ and R₅ is halogen and the other is a halogen substituted 1-6C alkyl, or R₄ and R₅ are joined to form an aromatic ring or a substituted aromatic ring.

18. The method of claim 1, wherein R₄ and R₅ are joined to form a substituted 6-10C aromatic ring wherein a substituent is chosen from 1-6C alkoxy, halogen and halogen-substituted 1-6C alkyl.

19. The method of claim 1, wherein R₂ and R₃ are a 1-6C alkyl.